Na
Wang‡
ag,
Zhiqin
Deng‡
ag,
Qi
Zhu‡
c,
Jianxiong
Zhao
c,
Kai
Xie
f,
Peng
Shi
f,
Zhigang
Wang
e,
Xianfeng
Chen
d,
Feng
Wang
cg,
Jiahai
Shi
b and
Guangyu
Zhu
*ag
aDepartment of Chemistry, City University of Hong Kong, Hong Kong SAR, P. R. China. E-mail: guangzhu@cityu.edu.hk
bDepartment of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, P. R. China
cDepartment of Materials Science and Engineering, City University of Hong Kong, Hong Kong SAR, P. R. China
dSchool of Engineering, Institute for Bioengineering, The University of Edinburgh, Mayfield Road, Edinburgh, EH9 3JL, UK
eSchool of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, 518060, P. R. China
fDepartment of Biomedical Engineering, City University of Hong Kong, Hong Kong SAR, P. R. China
gCity University of Hong Kong Shenzhen Research Institute, Shenzhen, 518057, P. R. China
First published on 6th October 2021
The outcome of conventional platinum (Pt)-based chemotherapy is limited by reduced circulation, failure to accumulate in the tumor, and dose-limiting toxicity arising from non-controllable activation. To address these limitations, we present an erythrocyte-delivered and near-infrared (NIR) photoactivatable PtIV nanoprodrug for advanced cancer treatment. Compared with small molecule PtIV prodrugs, this nanoprodrug exhibits significantly enhanced stability, prolonged circulation in the blood, and minimized side effects. The hitchhiking of the nanoprodrug on erythrocytes dramatically increases Pt accumulation in the tumor. Upon irradiation, the nanoprodrug releases oxaliplatin in a controllable manner, resulting in significant antitumor activity against breast tumors in vivo, as evidenced by the complete elimination of tumors from a single-dose injection. Additionally, this nanoprodrug is associated with remarkably enhanced immunopotentiation. Our study highlights an efficient strategy to overcome the shortcomings of traditional Pt-based chemotherapy via the erythrocyte-mediated delivery of an NIR-activatable nanoprodrug of oxaliplatin, a clinically used anticancer drug.
Recently, PtIV-based anticancer prodrugs have been studied extensively, with the aim of reducing the side effects and drug resistance associated with the original PtII anticancer drugs such as oxaliplatin.22–28 The administration of PtIV prodrugs, however, still faces significant challenges. For example, small-molecule PtIV prodrugs may not be stable enough in the circulation system and are also limited by an insufficient circulatory half-life, which reduces Pt accumulation in tumor tissues and thus restricts the drug efficacy.29,30 Additionally, conventional PtIV prodrugs do not have the property of controllable activation, leading to adverse effects in off-target tissues.31 Although small-molecule photoactivatable PtIV prodrugs have been developed, their activation wavelengths still fall within the visible spectrum and are subject to limited penetration depths.32–39 Furthermore, although platinum drugs such as oxaliplatin have been reported to induce immunogenic cell death (ICD), most of these studies were carried out in vitro.40–42 The prolonged circulation of oxaliplatin may significantly enhance the associated immune response induced in vivo. Taken together, a comprehensive study to obtain an NIR-activatable and clinical drug-based PtIV complex that exhibits enhanced circulation and elicits an elevated immune response in vivo is warranted.
To address these challenges, we report the development of an erythrocyte-delivered, NIR-activatable, and multifunctional PtIV nanoprodrug based on oxaliplatin for advanced cancer therapy. This nanoprodrug exhibited significantly enhanced stability in the blood compared with the small-molecule PtIV prodrug. Prolonged circulation and enhanced tumor accumulation of the PtIV nanoprodrug were achieved through auto-binding to erythrocytes in the bloodstream. Following NIR activation of the nanoprodrug, dramatically improved chemotherapeutic outcomes and minimal adverse side effects were observed in vivo. Furthermore, an enhanced immune response was observed due to increased drug accumulation in the tumor tissue. To the best of our knowledge, this is the first example of an erythrocyte-delivered and NIR-activatable PtIV complex based on oxaliplatin, a clinically used Pt-based chemotherapeutic.
The polyethylenimine (PEI)-capped NaYbF4:Er@NaYF4:Yb/Nd@NaYF4:Ca NCs were first synthesized,46,47 characterized (Fig. 1A and S1–S3, Table S1†), and verified to be excited at 808 nm to generate upconversion luminescence (UCL) emission at around 670 nm (Fig. 1B). The photoactivatable small-molecule PtIV prodrug, PPA-PtIV-COOH (Fig. S4–S9†), was loaded after conjugation with PEI-NCs via amine groups. Due to the overlap of the photoluminescence of NCs and the absorption of PPA-PtIV-COOH (Fig. 1B and C), the generated emission at 670 nm from PEI-NCs may further photoactivate the PtIV prodrug to release oxaliplatin. The synthesized PPA-PtIV-NCs were characterized by TEM (Fig. 1D and S10†), and the successful conjugation of PPA-PtIV-COOH onto PEI-NCs was confirmed by FT-IR, diameter, and zeta potential measurements (Fig. S11 and Table S1†). The loading capacity (LC%, wt%) of the PtIV prodrug on NCs reached as high as 22% (wt%; Fig. 1E). The photo-controllable drug release property of PPA-PtIV-NCs was confirmed, and the result clearly indicates that in the presence of a reducing agent, the nanocomplex is quite stable in the dark but can efficiently release oxaliplatin upon NIR irradiation (Fig. S12†). The level of generated 1O2 upon irradiation was also determined.48 PPA-PtIV-NCs with the highest loading capacity of 22% displayed a high potency of 1O2 generation (Fig. S13†) and were selected for the following investigations. Such a high drug-loading amount is advantageous for subsequent cancer therapy.
Subsequently, the photocytotoxicity of PPA-PtIV-NCs was examined in 4T1 (murine breast), MCF-7 (human breast), platinum-sensitive A2780 (human ovarian), and platinum-resistant A2780cisR (human ovarian) cancer cells. A time-dependent cellular accumulation experiment shows that most of the nanocomplex accumulated in the cells after 2 h (Fig. S14†). Thus, this treatment time was selected for further in vitro biological tests. The photocytotoxicity of PPA-PtIV-NCs was examined by a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. The cancer cells were treated with various concentrations of PPA-PtIV-NCs for 2 h in the dark, and then irradiated with an 808 nm continuous-wave (CW) diode laser at a power density of 0.5 W cm−2 for 5 min. At this power density, the laser itself had negligible effects on the cell viability (Fig. 1F–I). Without irradiation, the nanocomplex displayed low cytotoxicity in both the cancer cells and MRC-5 normal human lung fibroblasts (Fig. 1J), indicating its biocompatibility. Upon irradiation, PPA-PtIV-NCs were able to kill cancer cells. For example, the cell viabilities of 4T1 cells treated with 2 μg mL−1 PPA-PtIV-NCs without and with NIR irradiation were 85.3 ± 7.6% and 33.2 ± 4.4%, respectively, showing that PPA-PtIV-NCs had NIR-controlled cell-killing capability (Fig. 1F). This dramatic photocytotoxicity was also observed in other cell lines (Fig. 1G and H). Remarkably, PPA-PtIV-NCs showed a strong photocytotoxicity profile in the platinum-resistant A2780cisR cells, in which the cell viability decreased to 4.4 ± 1.6% upon treatment with 2 μg mL−1 PPA-PtIV-NCs (Fig. 1I). The photocytotoxicity of PPA-PtIV-COOH was also tested (Fig. S15 and S16†). The photocytotoxicity results well substantiate that the as-synthesized PPA-PtIV-NCs can effectively kill cancer cells upon photoactivation.
We next evaluated the delivery efficiency and photoactivation of our nanocomplex in cancer cells. Compared with the small-molecule PtIV prodrug, a significantly elevated level of Pt accumulation was observed in the cancer cells after treatment with the nanocomplex. For example, the Pt levels were 41.5 ± 3.1 ng and 851.1 ± 161.7 ng per 106 cells after treatment with the same concentration of PPA-PtIV-COOH and PPA-PtIV-NCs ([Pt] = 5.7 μM), respectively (Fig. S17†). This 20-fold increase in Pt accumulation in the presence of the nanocomplex clearly indicates the efficient delivery of the PtIV prodrug into the cancer cells. The level of Pt in the genomic DNA was subsequently measured in the cells treated with PPA-PtIV-NCs. An 8-fold increase in the level of Pt in the genomic DNA was detected after irradiation, compared to the level without irradiation (Fig. S18†). Since PtIV prodrugs can only efficiently bind to DNA after reduction to their Pt(II) species,39 this result clearly shows the efficient photo-controllable activation of the nanocomplex in cancer cells. Furthermore, intracellular reactive oxygen species (ROS) were generated after treatment with PPA-PtIV-NCs (Fig. S19†), indicating that this nanocomplex can kill cancer cells using a mode of combined chemo-photodynamic therapy.
Next, we endeavored to functionalize the nanocomplex with an erythrocyte-binding ability to achieve our original goals. Due to the presence of additional free amino groups on the surface, a linker O-[N-(6-maleimidohexanoyl)aminoethyl]-O′-[3-(N-succinimidyloxy)-3-oxopropyl]polyethylene glycol 3000 (NHS-PEG3k-MAL) was covalently loaded onto the surface of the nanocomplex to obtain PEG3k/PPA-PtIV-NCs. Subsequently, the ERY1 peptide was conjugated on PEG3k/PPA-PtIV-NCs through a reaction of the thiol-reactive maleimide on the distal end of the PEG3k and the C-terminus cysteine residue of the peptide. ERY1 is a synthetic 12-aa peptide that has strong and specific biophysical targeting of an antigen to the surface of mouse erythrocytes in situ through binding to glycophorin-A (GYPA).49 The resultant PtIV nanoprodrug is designated as ERY1-PEG3k/PPA-PtIV-NCs (Scheme 1). The conjugations were confirmed by TEM, ζ potential, size distribution, and FT-IR measurements (Fig. 2A, B, and S11, Table S1†). The strong photocytotoxicity presented by ERY1-PEG3k/PPA-PtIV-NCs was also confirmed (Fig. S20†).
The stability of PtIV in the dark was further examined in fresh mouse whole blood via reversed-phase high-performance liquid chromatography (RP-HPLC). The nanoprodrug showed significantly increased stability compared to its corresponding small molecule. Following incubation in mouse whole blood for 9 h at 37 °C, only 28.9 ± 6.7% of PPA-PtIV-COOH remained intact. In contrast, structural integrity was retained in 71.2 ± 2.5% of PPA-PtIV-NCs under the same condition. Furthermore, ERY1-PEG3k/PPA-PtIV-NCs exhibited the highest stability in the blood, as more than 91.0 ± 2.7% of PtIV remained intact after 24 h (Fig. 2C). The calculated half-lives (t1/2) were 4.2 ± 0.3 h, 14.3 ± 0.5 h, and 91.4 ± 15.1 h for PtIV in PPA-PtIV-COOH, PPA-PtIV-NCs, and ERY1-PEG3k/PPA-PtIV-NCs, respectively. This result evidently suggests the improved stability of our PtIV nanoprodrug in fresh mouse blood and points to its potential for effective in vivo utilization.
The ability of the functionalized nanoprodrug to bind erythrocytes was subsequently confirmed using scanning electron microscopy (SEM). For PEG3k/PPA-PtIV-NCs, no round nanoparticles were observed on the surface of the cells, and erythrocytes retained their physical integrity with a smooth surface (Fig. S21A and S21B†). After incubation, however, the ERY1-conjugated PtIV nanoprodrug was able to attach to the surface of erythrocytes (Fig. S21C and S21D†). These results are attributed to the specific binding properties of the ERY1 peptide. To better analyze the binding of the nanoprodrug to erythrocytes, confocal laser scanning microscopy (CLSM) was used for further visualization. Erythrocytes incubated with ERY1-PEG3k/PPA-PtIV-NCs showed a strong fluorescence intensity, indicating effective attachment to the surface of erythrocytes. In comparison, erythrocytes incubated with PEG3k/PPA-PtIV-NCs showed a 10.5-fold weaker fluorescent signal, representing very limited binding to erythrocytes (Fig. 2D and E and S22†). Furthermore, the PPA signal detected using flow cytometry indicated that ERY1-PEG3k/PPA-PtIV-NCs were attached on the surface of erythrocytes in the greatest abundance (Fig. S23 and S24†). The ERY1 peptide is believed to increase binding to the glycophorin A (GYPA) epitope on the erythrocyte membrane.50 To determine whether ERY1-PEG3k/PPA-PtIV-NCs binds to erythrocytes at the GYPA epitope, a fluorescence-conjugated GYPA antibody was used. A GYPA+ fluorescent signal would indicate binding of the GYPA antibody to the erythrocyte surface. In contrast, a lack of GYPA signal would indicate that the ERY1-conjugated PtIV nanoprodrug has bound to the available GYPA docking sites on the erythrocytes, thus preventing the antibody from binding. Using this rationale, the binding efficiency of PEG3k/PPA-PtIV-NCs to erythrocytes was determined to be as low as 1%, which is similar to that observed for untreated erythrocytes. In contrast, 98% of the ERY1-modified nanoprodrug was bound to erythrocytes via the GYPA site (Fig. S25†). A subsequent quantitative analysis of the Pt contents of these erythrocytes using ICP-OES yielded results consistent with the flow cytometry observations (Fig. S26†). These results clearly imply the erythrocyte-binding ability of the ERY1-conjugated nanoprodrug via the GYPA epitope.
The antitumor activity and immune response generated from our nanoprodrug in vivo were subsequently tested. The maximum tolerated dose (MTD) was determined to be 2.5 μmol-Pt kg−1 in BALB/c mice for single intravenous (i.v.) injection (Fig. S27†). It is well known that small-molecule Pt drugs suffer from high clearance and short circulation time with a half-life of only a few hours.51 Such rapid clearance limits the use of Pt drugs in cancer treatment because the drug cannot efficiently reach the target site with a certain level in a restricted period. With the advances of our PtIV nanoprodrug, the accumulation in the tumor site is expected to be improved by erythrocyte shuttling during circulation in the bloodstream. To evaluate the circulation half-life in blood vessels, PPA-PtIV-COOH, PEG3k/PPA-PtIV-NCs, and ERY1-PEG3k/PPA-PtIV-NCs were injected via the tail vein. The blood was collected by retro-orbital puncture from each anesthetized mouse at ten continuous time points. The curves of Pt concentration in the mice bloodstream indicated that the three complexes had different pharmacokinetic profiles. For the small molecule, the Pt concentration in the bloodstream decreased rapidly within the first 1 h and then declined slowly with a long terminal phase (Fig. 3A). For the PEGylated nanocomplex, a slow increase in Pt concentration was observed in the first 1 h (Fig. 3B). For the ERY1-modified PtIV nanoprodrug, however, the Pt concentration in the blood kept at a relatively flat level once injected (Fig. 3C), suggesting a quick redistribution in the blood through its strong erythrocyte-anchoring property and subsequent circulation to the whole body. The calculated circulation t1/2 of the small-molecule PPA-PtIV-COOH was only 0.79 h, while the erythrocyte-delivered PtIV nanoprodrug was as high as 907.76 h (Table S2†). All these data confirm that our ERY1-functionalized PtIV nanoprodrug has significantly improved circulation time in vivo over the free small molecules by rapidly attaching to the erythrocytes.
![]() | ||
Fig. 3 Pharmacokinetic tests and anticancer evaluation in 4T1 tumor-bearing BALB/c mice after intravenous (i.v.) injection with various complexes. The Pt concentration curve in plasma at each time point is from single dose i.v. injection of (A) PPA-PtIV-COOH, (B) PEG3k/PPA-PtIV-NCs, and (C) ERY1-PEG3k/PPA-PtIV-NCs. (D) The Pt accumulation in the tumor determined by ICP-OES at each corresponding time point indicated. (E) Anticancer activity after treatment with various complexes. The indicated complexes were i.v. injected once on Day 0 and treated with or without irradiation. Irradiation conditions: 660 nm laser (100 mW cm−2) for 10 min per mouse, 808 nm laser (0.5 W cm−2) for 30 min (5 min irradiation with 5 min interval) per mouse. Experimental details are described in the ESI.† (F) Photograph of excised tumors at the endpoint (Day 14) of anticancer evaluation. (G) Tumor weights of different treatment groups in the 4T1 xenograft model after the termination of anticancer evaluation. Mean ± SD; n = 3. *, p <0.05; ***, p <0.001; ns, no significance. Student's t-test. |
Based on the in vitro studies and in vivo pharmacokinetic results, we expect that our ERY1-functionalized PtIV nanoprodrug may have elevated accumulation in the tumor site after a prolonged circulation. To corroborate this hypothesis, a murine mammary adenocarcinoma 4T1 xenograft model was established to investigate the biodistribution of various complexes in vivo. As observed by a bio-imaging system, the fluorescence intensity in the tumor treated with ERY1-PEG3k/PPA-PtIV-NCs remained at a relatively high level (Fig. S28A†). This result indicates the strong accumulation of our nanoprodrug in the tumor after the elongated circulation. For clearer observation, the mice were sacrificed at different time points, and the major organs and tumors were harvested for ex vivo imaging. As shown from the fluorescence images of excised tissues and the corresponding fluorescence intensity, the ERY1-functionalized nanoprodrug succeeded in accumulating in the tumor and maintaining at a high level (Fig. S28B†). To better quantify the distribution in target tissues, Pt accumulation in the tumor was analyzed by ICP-OES. After i.v. injection via the tail vein, the level of Pt in the tumor decreased gradually in all the test groups, except for ERY1-PEG3k/PPA-PtIV-NCs (Fig. 3D). Compared with the small-molecule or non-functionalized nanocomplex, this ERY1-functionalized nanoprodrug shows significantly elevated accumulation in the tumor. For example, compared with PEG3k/PPA-PtIV-NCs, a 6.6-fold increase in the Pt level in the tumor was observed after 17 h, and the fold increase was as high as 17.3 after 24 h. These results provide strong evidence that ERY1-PEG3k/PPA-PtIV-NCs accumulate strikingly efficiently in the tumor after circulation in the body. With hitchhiking of the nanoprodrug on erythrocytes, the Pt level increased steadily in the tumor site, which can be utilized to produce a stronger chemotherapeutic effect.
Subsequently, the in vivo antitumor activity of our nanoprodrug ERY1-PEG3k/PPA-PtIV-NCs was examined using a 4T1 tumor model. Tumor-bearing BALB/c mice were intravenously (i.v.) injected once with the different complexes at a dose of 2.5 μmol-Pt kg−1. Three hours later, the tumors were irradiated with NIR light at different frequencies (Fig. S29†). As indicated in Fig. 3E, S30, and S31,† the control group, which was administered an equal volume of 0.9% saline, demonstrated no antitumor effects either with or without NIR irradiation. Without irradiation, the mice treated with the small molecule PPA-PtIV-COOH did not show significant tumor inhibition relative to the untreated groups; after irradiation at 660 nm, a limited anticancer effect was achieved in the group treated with the small molecule. In the group treated with ERY1-PEG3k/PPA-PtIV-NCs, weak tumor growth inhibition was observed without irradiation, which was likely due to a slow reduction of the PtIV prodrug in the nanoprodrug at the tumor site. An increased antitumor effect was observed in the mice treated with ERY1-PEG3k/PPA-PtIV-NCs after three rounds of NIR irradiation, indicating the effective photoactivation of the nanoprodrug. Notably, the strongest antitumor effect was achieved with ERY1-PEG3k/PPA-PtIV-NCs and seven rounds of irradiation. At the end of the study, the tumor volume in this group showed a significant reduction in comparison to the volumes in the other 7 groups (p <0.001). The average tumor volume was only 16.1 ± 15.4 mm3 in the mice treated with ERY1-PEG3k/PPA-PtIV-NCs and seven rounds of NIR irradiation, which represents reduction of 98.7% and 98.6% relative to those treated with PPA-PtIV-COOH and PEG3k/PPA-PtIV-NCs, respectively. More intriguingly, two of the five tumors were completely resolved in the group treated with our PtIV nanoprodrug (Fig. 3F and S32†). The lowest tumor weights were also observed in the ERY1-PEG3k/PPA-PtIV-NCs-treated group (Fig. 3G). These results are likely due to the tendency of the nanoprodrug to accumulate in the tumors after being transported by the erythrocytes, and continuous drug activation mediated by several rounds of irradiation.
Despite killing cancer cells by causing DNA damage, oxaliplatin is recently identified as an immunomodulator to enhance the response of cytotoxic T lymphocytes through ICD.52,53 Moreover, cell debris caused by cytotoxic oxaliplatin and PDT could act as antigens to recruit intratumoral infiltration of immune cells and further strengthen cancer treatment.13 We expect that the enhanced accumulation of the PtIV nanoprodrug can precisely and adequately induce a potent immune response to improve the cancer treatment in vivo. The antitumor immune response was subsequently examined by investigating the frequencies of intratumoral T cells, including CD4+ (CD3+CD4+ as the marker) and CD8+ (CD3+CD8+ as the marker) T cells, in collected tumors via flow cytometric analysis. The isolated single cells from the tumors were obtained and stained with fluorochrome-conjugated CD3, CD4, and CD8 antibodies as the T cell surface markers.54 It is well known that effector CD4+ T cells released from the lymph node could reach the tumor by blood vessels to kill tumor cells after immune stimulation.55 Besides, CD8+ T cells act as the cytotoxic agent in the front line of the tumor microenvironment.56 Animals treated with PPA-PtIV-COOH without irradiation have 1.0% CD4+ and 1.8% CD8+ T lymphocytes in the tumor, similar to the untreated ones (1.0% CD4+ and 1.4% CD8+, Fig. 4). Upon irradiation after treatment with the small molecule or PEG3k/PPA-PtIV-NCs, the frequencies of CD4+ and CD8+ T cells did not significantly increase in the tumor, indicating that the small molecule itself and the nonfunctionalized nanoparticles were not strong enough to activate sufficient antitumor immune response (Fig. 4). The result could be attributed to unsatisfactory tumor accumulation capacity with only a single dose. In contrast, the mice treated with ERY1-PEG3k/PPA-PtIV-NCs after 808 nm NIR irradiation showed significantly higher frequencies of CD4+ and CD8+, especially when more rounds of irradiation were applied. For instance, with the treatment of our nanoprodrug, the frequencies of CD4+ and CD8+ T cells were 18.5% and 19.5%, which were 14.5-fold and 7.2-fold higher than those from the photoactivated small molecule, respectively. Hence, our PtIV nanoprodrug shuttled by erythrocytes exhibited a significantly enhanced synergistic immunopotentiation action compared with the small molecule or the nonfunctionalized nanoparticles alone upon single injection.
The safety of anticancer drugs is another major concern during the evaluation of antineoplastics.57 Due to the controllable activation property of our PtIV nanoprodrug, we anticipate that the multifunctional nanoprodrug may have low damage to normal tissues. Subsequently, the bodyweight of all the treated mice was measured every other day during the observation period. Minimal variations have been observed for all the tested groups (Fig. S33†). After treatment with ERY1-PEG3k/PPA-PtIV-NCs and seven rounds of irradiation, the spleen weights recovered to the normal level (Fig. S34†). Meanwhile, blood biochemical indexes were also measured to evaluate the systemic toxicity on day 14 post-injection. The concentrations of aspartate transaminase (AST), alanine aminotransferase (ALT), creatinine, uric acid (UA), and blood urea nitrogen (BUN) had no significant alterations after treatments (Fig. S35†). Besides, no obvious change was found in all the major organs from the treatment groups through the hematoxylin and eosin (H&E) staining (Fig. S36†). Taken together, these assays verify the safety and minimal systemic toxicity of our ERY1-PEG3k/PPA-PtIV-NC nanoprodrug that displays more effective anticancer activity over the small molecule.
Footnotes |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/d1sc02941j |
‡ These authors contributed equally to this work. |
This journal is © The Royal Society of Chemistry 2021 |